<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human" exact="respiratory" post="disease: detection, mechanisms and treatment KangShuntongabPengWenyaoabZhuYuhaoabLuShiyaoabZhouMinabLinWeiaWuWenfangaHuangShuaJiangLipingcLuoXuandDengMeichundengmch@csu.edu.cnab⁎[a], [b], [c], [d],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="as long as the COVID-19 resource centre remains active. Abstract" exact="Viral" post="respiratory diseases such as severe acute respiratory syndrome (SARS)"/>
 <result pre="long as the COVID-19 resource centre remains active. Abstract Viral" exact="respiratory" post="diseases such as severe acute respiratory syndrome (SARS) and"/>
 <result pre="centre remains active. Abstract Viral respiratory diseases such as severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)"/>
 <result pre="remains active. Abstract Viral respiratory diseases such as severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS) always"/>
 <result pre="active. Abstract Viral respiratory diseases such as severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS) always pose"/>
 <result pre="such as severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS) always pose a severe threat to people."/>
 <result pre="as severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS) always pose a severe threat to people. First"/>
 <result pre="affected many provinces in China and multiple countries worldwide. The" exact="viral" post="outbreak has aroused panic and a public-health emergency around"/>
 <result pre="a public-health emergency around the world, and the number of" exact="infections" post="continues to rise. However, the causes and consequences of"/>
 <result pre="continues to rise. However, the causes and consequences of the" exact="pneumonia" post="remain unknown. To effectively implement epidemic prevention, early identification"/>
 <result pre="implement epidemic prevention, early identification and diagnosis are critical to" exact="disease" post="control. Here we scrutinise a series of available studies"/>
 <result pre="the clinical manifestations, detection methods and treatment options for the" exact="disease" post="caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19), and"/>
 <result pre="and treatment options for the disease caused by SARS-CoV-2, named" exact="coronavirus disease" post="2019 (COVID-19), and also propose potential strategies for preventing"/>
 <result pre="treatment options for the disease caused by SARS-CoV-2, named coronavirus" exact="disease" post="2019 (COVID-19), and also propose potential strategies for preventing"/>
 <result pre="At the end of 2019, several patients were diagnosed with" exact="pneumonia" post="of unknown cause, epidemiologically associated with the same seafood"/>
 <result pre="This condition attracted the attention of the Chinese Center for" exact="Disease" post="Control and Prevention (CDC), who immediately launched an emergency"/>
 <result pre="of international concern (PHEIC). The causative agent of the unidentified" exact="pneumonia" post="has been confirmed as a novel coronavirus by sequencing"/>
 <result pre="it was found to be distinct both from Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus"/>
 <result pre="was found to be distinct both from Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)"/>
 <result pre="both from Middle East respiratory syndrome coronavirus (MERS-CoV) and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [1,2]. Coronaviruses are single-stranded RNA"/>
 <result pre="from Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [1,2]. Coronaviruses are single-stranded RNA viruses"/>
 <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [1,2]. Coronaviruses are single-stranded RNA viruses belonging"/>
 <result pre="originally denoted 2019 novel coronavirus (2019-nCoV) and officially renamed severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee"/>
 <result pre="denoted 2019 novel coronavirus (2019-nCoV) and officially renamed severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on"/>
 <result pre="2019 novel coronavirus (2019-nCoV) and officially renamed severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy"/>
 <result pre="by the International Committee on Taxonomy of Viruses, and the" exact="disease" post="it causes, namely coronavirus disease 2019 (COVID-19), has quickly"/>
 <result pre="on Taxonomy of Viruses, and the disease it causes, namely" exact="coronavirus disease" post="2019 (COVID-19), has quickly become of tremendous concern worldwide."/>
 <result pre="Taxonomy of Viruses, and the disease it causes, namely coronavirus" exact="disease" post="2019 (COVID-19), has quickly become of tremendous concern worldwide."/>
 <result pre="Asia, Europe, North America, South America, Africa and Oceania. The" exact="disease" post="is potentially zoonotic, with an estimated mortality rate of"/>
 <result pre="rate of 2–5%. Person-to-person transmission may occur through contact and" exact="respiratory" post="transmission or possibly by the faecal–oral route. Currently, the"/>
 <result pre="possibly by the faecal–oral route. Currently, the number of confirmed" exact="infections" post="has been increasing daily but there is no definite"/>
 <result pre="to the latest research, useful information for control of the" exact="disease" post="is urgently required and is highly essential. 2 Virology"/>
 <result pre="a diameter of 60–160 nm observed by electron microscopy. Each" exact="viral" post="particle is enveloped and contains a single-stranded positive-sense RNA"/>
 <result pre="three proteins: the M protein binds the nucleocapsid and enhances" exact="viral" post="assembly and budding; the E protein is involved in"/>
 <result pre="viral assembly and budding; the E protein is involved in" exact="viral" post="morphogenesis, release and pathogenesis; and the S protein contributes"/>
 <result pre="in nature for humans and animals, usually causing gastrointestinal or" exact="respiratory" post="infections and sometimes involving important organs such as the"/>
 <result pre="nature for humans and animals, usually causing gastrointestinal or respiratory" exact="infections" post="and sometimes involving important organs such as the liver,"/>
 <result pre="and sometimes involving important organs such as the liver, kidney," exact="heart" post="and brain. They are sensitive to ultraviolet rays and"/>
 <result pre="before 2019, only six coronaviruses were proven to cause human" exact="respiratory" post="diseases: (i) HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E, which lead"/>
 <result pre="HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E, which lead to only mild" exact="upper" post="respiratory disease, rarely bring about severe disease in humans;"/>
 <result pre="HCoV-NL63, HCoV-OC43 and HCoV-229E, which lead to only mild upper" exact="respiratory" post="disease, rarely bring about severe disease in humans; and"/>
 <result pre="to only mild upper respiratory disease, rarely bring about severe" exact="disease" post="in humans; and (ii) SARS-CoV and MERS-CoV, which attack"/>
 <result pre="in humans; and (ii) SARS-CoV and MERS-CoV, which attack the" exact="lower" post="respiratory tract and induce severe respiratory syndrome. Sequence analysis"/>
 <result pre="humans; and (ii) SARS-CoV and MERS-CoV, which attack the lower" exact="respiratory" post="tract and induce severe respiratory syndrome. Sequence analysis shows"/>
 <result pre="MERS-CoV, which attack the lower respiratory tract and induce severe" exact="respiratory" post="syndrome. Sequence analysis shows that SARS-CoV-2 has a typical"/>
 <result pre="and the evolutionary rate, in turn providing important implications for" exact="disease" post="progression, drug trials and vaccine development. Zhou et al."/>
 <result pre="and vaccine development. Zhou et al. reported that the full-length" exact="viral" post="genome sequences from patients in the early outbreak were"/>
 <result pre="virus from the family Coronaviridae [1]. Phylogenetic analysis of the" exact="complete" post="viral genome revealed that the coronavirus was most closely"/>
 <result pre="from the family Coronaviridae [1]. Phylogenetic analysis of the complete" exact="viral" post="genome revealed that the coronavirus was most closely related"/>
 <result pre="the bat coronavirus by accumulating favourable genetic alterations for human" exact="infection" post="[10]. Epitopes in SAR-CoV-2 structural proteins were differentially recognised"/>
 <result pre="sequence diversity. Although many scientists believe that bats are the" exact="intermediate" post="host, most species of bats live in tropical or"/>
 <result pre="is generally known that bats may spread viruses to other" exact="intermediate" post="hosts such as wild animals or livestock, from which"/>
 <result pre="metagenomic sequencing [15]. Hence, pangolins should be considered as possible" exact="intermediate" post="hosts and should be removed from markets to prevent"/>
 <result pre="by routine anti-infective drugs, as well as cough, headache and" exact="muscle" post="pain or fatigue [16]. Other clinical symptoms observed at"/>
 <result pre="pain or fatigue [16]. Other clinical symptoms observed at a" exact="lower" post="frequency include elevated troponin levels, diarrhoea, myalgia and myocarditis"/>
 <result pre="a lower frequency include elevated troponin levels, diarrhoea, myalgia and" exact="myocarditis" post="[16]. It should be emphasised that some asymptomatic persons"/>
 <result pre="of other organs, primarily renal impairment, and patients with underlying" exact="cardiovascular" post="diseases often demonstrated co-morbid heart failure [18]. Patients gradually"/>
 <result pre="impairment, and patients with underlying cardiovascular diseases often demonstrated co-morbid" exact="heart" post="failure [18]. Patients gradually develop initial symptoms in the"/>
 <result pre="heart failure [18]. Patients gradually develop initial symptoms in the" exact="cardiovascular" post="system, digestive system and nervous system, which increases the"/>
 <result pre="significant symptom aggravation such as dyspnoea or the appearance of" exact="acute respiratory distress syndrome" post="(ARDS) was 7 days (range 1–20 days), which is"/>
 <result pre="symptom aggravation such as dyspnoea or the appearance of acute" exact="respiratory" post="distress syndrome (ARDS) was 7 days (range 1–20 days),"/>
 <result pre="such as dyspnoea or the appearance of acute respiratory distress" exact="syndrome" post="(ARDS) was 7 days (range 1–20 days), which is"/>
 <result pre="the newly released pneumonitis diagnosis and treatment plan for novel" exact="coronavirus infection," post="severe patients often have dyspnoea and/or hypoxaemia 1 week"/>
 <result pre="of the illness. Serious cases can quickly progress to ARDS," exact="septic shock," post="irreformable metabolic acidosis, coagulopathy and multiple organ failure. Nearly"/>
 <result pre="Serious cases can quickly progress to ARDS, septic shock, irreformable" exact="metabolic acidosis," post="coagulopathy and multiple organ failure. Nearly 80% of patients"/>
 <result pre="can quickly progress to ARDS, septic shock, irreformable metabolic acidosis," exact="coagulopathy" post="and multiple organ failure. Nearly 80% of patients have"/>
 <result pre="Lung involvement is present in all cases [19,20], with most" exact="chest" post="computed tomography (CT) images showing lesions in multiple lung"/>
 <result pre="co-existing with consolidation shadows or cord-like shadows are observed. Since" exact="respiratory" post="support is administered to most patients, oxygen saturation can"/>
 <result pre="but it is poor for the elderly and those with" exact="chronic" post="underlying diseases. Symptoms in children are relatively mild. Regarding"/>
 <result pre="are relatively mild. Regarding the current situation, the source of" exact="infection" post="is mainly infected patients, but the possibility of asymptomatic"/>
 <result pre="infection is mainly infected patients, but the possibility of asymptomatic" exact="infection" post="should not be ignored. Respiratory droplets and close contacts"/>
 <result pre="but the possibility of asymptomatic infection should not be ignored." exact="Respiratory" post="droplets and close contacts are the key routes of"/>
 <result pre="found that the ACE2 cell receptor is highly expressed on" exact="type II" post="alveolar epithelial cells, oesophageal epithelium, stratified epithelial cells, and"/>
 <result pre="ACE2 cell receptor is highly expressed on type II alveolar" exact="epithelial" post="cells, oesophageal epithelium, stratified epithelial cells, and even in"/>
 <result pre="expressed on type II alveolar epithelial cells, oesophageal epithelium, stratified" exact="epithelial" post="cells, and even in absorptive intestinal epithelial cells from"/>
 <result pre="oesophageal epithelium, stratified epithelial cells, and even in absorptive intestinal" exact="epithelial" post="cells from the ileum and colon [21]. Their bioinformatics"/>
 <result pre="transcriptomes suggests that the digestive tract may serve as an" exact="infection" post="pathway for SARS-CoV-2. The spread and infection of the"/>
 <result pre="serve as an infection pathway for SARS-CoV-2. The spread and" exact="infection" post="of the virus are complex problems requiring co-operation from"/>
 <result pre="perspectives including medicine, biology and fluid mechanics to give a" exact="complete" post="answer. 5 Detection 5.1 General examination Mild patients may"/>
 <result pre="fluid mechanics to give a complete answer. 5 Detection 5.1" exact="General" post="examination Mild patients may have no positive signs, whilst"/>
 <result pre="[22]. 5.2 Chest imaging Suspected or confirmed cases should undergo" exact="chest" post="radiography as early as possible and a chest CT"/>
 <result pre="should undergo chest radiography as early as possible and a" exact="chest" post="CT scan when necessary [23]. In the early phase"/>
 <result pre="when necessary [23]. In the early phase of the disease," exact="chest" post="images show interstitial changes and multiple small plaques, especially"/>
 <result pre="the middle and outer zones of the lung with multiple" exact="infiltrating" post="shadows and/or ground-glass opacities. Patients may have a single"/>
 <result pre="Conversely, lung consolidation may occur in severe cases in whom" exact="pleural" post="effusions are rarely seen. 5.3 Laboratory examination 5.3.1 Haematological"/>
 <result pre="routine blood changes after 3 days [22]. In some patients," exact="muscle" post="enzymes, liver enzymes and myohaemoglobin levels are increased. Otherwise,"/>
 <result pre="(ESR) and C-reactive protein (CRP) level, with normal procalcitonin level." exact="Severe" post="cases show progressively decreased blood lymphocyte counts and high"/>
 <result pre="show progressively decreased blood lymphocyte counts and high D-dimer levels." exact="Inflammatory" post="factors are often increased in severe and critical patients."/>
 <result pre="PCR (RT-PCR) Samples from suspected SARS-CoV-2 patients collected from the" exact="upper" post="respiratory tract (nasopharyngeal and oropharyngeal), lower respiratory tract (expectorated"/>
 <result pre="(RT-PCR) Samples from suspected SARS-CoV-2 patients collected from the upper" exact="respiratory" post="tract (nasopharyngeal and oropharyngeal), lower respiratory tract (expectorated sputum,"/>
 <result pre="patients collected from the upper respiratory tract (nasopharyngeal and oropharyngeal)," exact="lower" post="respiratory tract (expectorated sputum, endotracheal aspirate or bronchoalveolar lavage),"/>
 <result pre="collected from the upper respiratory tract (nasopharyngeal and oropharyngeal), lower" exact="respiratory" post="tract (expectorated sputum, endotracheal aspirate or bronchoalveolar lavage), blood"/>
 <result pre="addition, RT-PCR tests may be falsely negative due to insufficient" exact="viral" post="material or operational error. Some patients with negative RT-PCR"/>
 <result pre="Some patients with negative RT-PCR results may present with positive" exact="chest" post="CT findings for COVID-19, meaning that PCR results can"/>
 <result pre="assist clinical diagnosis and evaluation but the possibility of the" exact="disease" post="cannot be confirmed or ruled out. For individuals with"/>
 <result pre="for the new coronavirus. In this way, interference from other" exact="respiratory" post="virus genomes can also be minimised. Theoretically, as long"/>
 <result pre="was modified from Wrapp et al. [38]. SARS-CoV-2 (2019-nCoV), severe" exact="acute" post="respiratory syndrome coronavirus 2 (2019 novel coronavirus). However, when"/>
 <result pre="modified from Wrapp et al. [38]. SARS-CoV-2 (2019-nCoV), severe acute" exact="respiratory" post="syndrome coronavirus 2 (2019 novel coronavirus). However, when SARS-CoV"/>
 <result pre="from Wrapp et al. [38]. SARS-CoV-2 (2019-nCoV), severe acute respiratory" exact="syndrome" post="coronavirus 2 (2019 novel coronavirus). However, when SARS-CoV attempts"/>
 <result pre="disorders. Referring to previous reports, patients infected with SARS-CoV had" exact="pulmonary" post="fibrosis due to CCL2. Cheung et al. observed the"/>
 <result pre="ACE2 on human cells [41] (Fig. 2 ). Infected lung" exact="epithelial" post="cells induce casein kinase II (CK II), which is"/>
 <result pre="the sera of SARS-CoV-infected patients account for the development of" exact="lung fibrosis." post="Fig. 2 Model of the angiotensin-converting enzyme 2 (ACE2)"/>
 <result pre="enzyme 2 (ACE2) signalling pathway involved in SARS-CoV-induced CCL2 expression." exact="Infection" post="of lung epithelial cells with SARS-CoV induces casein kinase"/>
 <result pre="signalling pathway involved in SARS-CoV-induced CCL2 expression. Infection of lung" exact="epithelial" post="cells with SARS-CoV induces casein kinase II (CK II)-mediated"/>
 <result pre="sera of SARS-CoV-infected patients may account for the development of" exact="lung fibrosis." post="Figure was modified from Chen et al. [41]. SARS-CoV,"/>
 <result pre="Figure was modified from Chen et al. [41]. SARS-CoV, severe" exact="acute" post="respiratory syndrome coronavirus; CCL2, chemokine (C-C motif) ligand 2."/>
 <result pre="was modified from Chen et al. [41]. SARS-CoV, severe acute" exact="respiratory" post="syndrome coronavirus; CCL2, chemokine (C-C motif) ligand 2. 7"/>
 <result pre="modified from Chen et al. [41]. SARS-CoV, severe acute respiratory" exact="syndrome" post="coronavirus; CCL2, chemokine (C-C motif) ligand 2. 7 Therapeutic"/>
 <result pre="broad spectrum [47]. Specific inhibitors of key proteases involved in" exact="viral" post="replication and proliferation are effective ways of killing viruses."/>
 <result pre="compounds include RNA proteases, membrane proteins, spike glycoproteins, polymerases and" exact="viral" post="envelope that act directly on the virus, as well"/>
 <result pre="main protease of SARS-CoV [47]. The first case of SARS-CoV-2-infected" exact="pneumonia" post="in the USA experienced significant improvement in clinical symptoms"/>
 <result pre="fusion inhibitor denoted EK1 that can significantly inhibit SARS-CoV-2 pseudovirus" exact="infection" post="in a dose-dependent manner [60]. 8 Treatment strategies 8.1"/>
 <result pre="issued several guidelines for the diagnosis and treatment of novel" exact="coronavirus pneumonia," post="none of which recommended specific drugs for COVID-19. According"/>
 <result pre="observed to have the ability to reduce MERS-CoV replication, improve" exact="pulmonary" post="function and reduce pulmonary lesions in Calu-3 cells and"/>
 <result pre="ability to reduce MERS-CoV replication, improve pulmonary function and reduce" exact="pulmonary" post="lesions in Calu-3 cells and mouse models [54]. It"/>
 <result pre="that in the Vero E6 cell model, remdesivir inhibits the" exact="infection" post="of SARS-CoV-2 virus, with an EC50 (half-maximal effective concentration)"/>
 <result pre="against SARS-CoV-2. As reported previously, the first case of new" exact="coronavirus pneumonia" post="treated in the USA received only supportive treatment for"/>
 <result pre="SARS-CoV-2. As reported previously, the first case of new coronavirus" exact="pneumonia" post="treated in the USA received only supportive treatment for"/>
 <result pre="nucleoside analogue that has been used in the treatment of" exact="hepatitis" post="C virus and respiratory syncytial virus. The antiviral mechanism"/>
 <result pre="been used in the treatment of hepatitis C virus and" exact="respiratory" post="syncytial virus. The antiviral mechanism involves interacting with virus"/>
 <result pre="MERS could be improved by the combination of ribavirin and" exact="type I" post="interferon [70]. However, side effects of ribavirin, such as"/>
 <result pre="addition, two meta-analyses of SARS and MERS case studies demonstrated" exact="limited" post="efficacy in treating patients with coronavirus respiratory syndrome [72,73]."/>
 <result pre="MERS case studies demonstrated limited efficacy in treating patients with" exact="coronavirus respiratory syndrome" post="[72,73]. Therefore, further studies are needed to determine whether"/>
 <result pre="case studies demonstrated limited efficacy in treating patients with coronavirus" exact="respiratory" post="syndrome [72,73]. Therefore, further studies are needed to determine"/>
 <result pre="studies demonstrated limited efficacy in treating patients with coronavirus respiratory" exact="syndrome" post="[72,73]. Therefore, further studies are needed to determine whether"/>
 <result pre="are needed to determine whether ribavirin can effectively treat novel" exact="coronavirus pneumonia" post="(COVID-19), and ribavirin and interferon are still in clinical"/>
 <result pre="needed to determine whether ribavirin can effectively treat novel coronavirus" exact="pneumonia" post="(COVID-19), and ribavirin and interferon are still in clinical"/>
 <result pre="is a protease inhibitor used in combined therapy for human" exact="immunodeficiency" post="virous (HIV) [74]. Lopinavir inhibits cleavage of the gag-pol"/>
 <result pre="are also considered as drugs for the treatment of novel" exact="coronavirus pneumonia" post="[81]. 8.1.3 Broad-spectrum antivirals Interferon (IFN) is a type"/>
 <result pre="also considered as drugs for the treatment of novel coronavirus" exact="pneumonia" post="[81]. 8.1.3 Broad-spectrum antivirals Interferon (IFN) is a type"/>
 <result pre="other neutralising antibodies for the prevention and treatment of SARS-CoV-2" exact="infection" post="[37]. However, the dose needs to be determined before"/>
 <result pre="of ARDS [86]. However, different studies suggest that glucocorticoids slow" exact="viral" post="clearance [87]. Clinical data are still needed to demonstrate"/>
 <result pre="Therefore, application of ACE inhibitors (ACEIs) and angiotensin II receptor" exact="type 1" post="(AT1R) inhibitors under the condition of close monitoring of"/>
 <result pre="is likely to reduce the damage in patients with SARS-CoV-2" exact="infection" post="[88]. XueBiJing is a traditional Chinese medicine injection commonly"/>
 <result pre="XueBiJing injection could significantly reduce the fatality rate of community-acquired" exact="pneumonia" post="[89]. Further reliable evidence is needed for potential Chinese"/>
 <result pre="with the aim of curtailing the geographic spread of the" exact="infection" post="[90]. Traveller symptom screening depends on the natural history"/>
 <result pre="the tests, that traveller screening outcomes were sensitive at a" exact="short" post="mean incubation period [91]. However, for longer incubation periods,"/>
 <result pre="To find theoretical reasons to support this method for preventing" exact="viral infection" post="with SARS-CoV-2, Fan et al. discussed from the perspective"/>
 <result pre="find theoretical reasons to support this method for preventing viral" exact="infection" post="with SARS-CoV-2, Fan et al. discussed from the perspective"/>
 <result pre="ACE2 receptor and exerting an antiviral effect to prevent SARS-CoV-2" exact="infection" post="[96]. 10 Conclusion SARS-CoV-2 is driving China's urgent public"/>
 <result pre="patients nationwide and globally, and the future development of the" exact="disease" post="is unclear but the public should pay attention to"/>
 <result pre="very contagious. References References 1WuF.ZhaoS.YuB.ChenY.M.WangW.SongS.G.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature579202026526910.1038/s41586-020-2008-332015508 2ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A pneumonia outbreak associated with a"/>
 <result pre="contagious. References References 1WuF.ZhaoS.YuB.ChenY.M.WangW.SongS.G.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature579202026526910.1038/s41586-020-2008-332015508 2ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A pneumonia outbreak associated with a new"/>
 <result pre="new coronavirus associated with human respiratory disease in ChinaNature579202026526910.1038/s41586-020-2008-332015508 2ZhouP.YangX.L.WangX.G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="zoonotic diseasesPathog Dis77201910.1093/femspd/ftaa006pii: ftaa006 8ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med382202072773310.1056/NEJMoa200101731978945 9BenvenutoD.GiovanettiM.CiccozziA.SpotoS.AngelettiS.CiccozziM.The 2019-new coronavirus"/>
 <result pre="ProvinceChin Med J (Engl)2020 Feb 710.1097/CM9.0000000000000744[Epub ahead of print] 17ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="(Engl)2020 Feb 710.1097/CM9.0000000000000744[Epub ahead of print] 17ChanJ.F.YuanS.KokK.H.ToK.K.ChuH.YangJ.A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="ChinaLancet395202049750610.1016/s0140-6736(20)30183-531986264 19ZhouY.YangL.HanM.HuangM.SunX.ZhenW.Clinical reports on early diagnosis of novel coronavirus (2019-nCoV)" exact="pneumonia" post="in stealth infected patientsPreprints2020202002015610.20944/preprints202002.0156.v1 20LiuY.YangY.ZhangC.HuangF.WangF.YuanJ.Clinical and biochemical indexes from"/>
 <result pre="20LiuY.YangY.ZhangC.HuangF.WangF.YuanJ.Clinical and biochemical indexes from 2019-nCoV infected patients linked to" exact="viral" post="loads and lung injurySci China Life Sci63202036437410.1007/s11427-020-1643-832048163 21ZhangH.KangZ.GongH.XuD.WangJ.LiZ.The digestive"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Mil Med Res72020410.1186/s40779-020-0233-632029004 23ShenK.YangY.WangT.ZhaoD.JiangY.JinR.Diagnosis, treatment, and prevention of"/>
 <result pre="version)Mil Med Res72020410.1186/s40779-020-0233-632029004 23ShenK.YangY.WangT.ZhaoD.JiangY.JinR.Diagnosis, treatment, and prevention of 2019 novel" exact="coronavirus infection" post="in children: experts' consensus statementWorld J Pediatr2020 Feb 710.1007/s12519-020-00343-7[Epub"/>
 <result pre="Med Res72020410.1186/s40779-020-0233-632029004 23ShenK.YangY.WangT.ZhaoD.JiangY.JinR.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: experts' consensus statementWorld J Pediatr2020 Feb 710.1007/s12519-020-00343-7[Epub"/>
 <result pre="CT findings and temporal changes in patients with the novel" exact="coronavirus pneumonia" post="(2019-nCoV): a study of 63 patients in Wuhan, ChinaEur"/>
 <result pre="findings and temporal changes in patients with the novel coronavirus" exact="pneumonia" post="(2019-nCoV): a study of 63 patients in Wuhan, ChinaEur"/>
 <result pre="Feb 1310.1007/s00330-020-06731-x[Epub ahead of print] 25YuF.DuL.OjciusD.M.PanC.JiangS.Measures for diagnosing and treating" exact="infections" post="by a novel coronavirus responsible for a pneumonia outbreak"/>
 <result pre="and treating infections by a novel coronavirus responsible for a" exact="pneumonia" post="outbreak originating in Wuhan, ChinaMicrobes Infect222020747910.1016/j.micinf.2020.01.00332017984 26ChuD.K.W.PanY.ChengS.M.S.HuiK.P.Y.KrishnanP.LiuY.Molecular diagnosis of"/>
 <result pre="2020;15:1311. doi: 10.1038/s41596-020-0302-z31548639 29RenL.L.WangY.M.WuZ.Q.XiangZ.C.GuoL.XuT.Identification of a novel coronavirus causing severe" exact="pneumonia" post="in human: a descriptive studyChin Med J (Engl)2020 Feb"/>
 <result pre="the receptor-binding domain of SARS corona virus spike protein blocks" exact="viral" post="entry into host cells via the human receptor ACE2Antiviral"/>
 <result pre="and infectivity of 2019-nCoV, a new coronavirus which caused a" exact="pneumonia" post="outbreak in Wuhan, ChinabioRxiv2020 Jan 2210.1101/2020.01.20.913368 34ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.Discovery of a"/>
 <result pre="2210.1101/2020.01.20.913368 34ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat originbioRxiv2020 Jan"/>
 <result pre="fibroblast collagen and transforming growth factor β1 gene expression by" exact="monocyte" post="chemoattractant protein-1 via specific receptorsJ Biol Chem2711996177791778410.1074/jbc.271.30.177798663511 40CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.Cytokine responses"/>
 <result pre="protein-1 via specific receptorsJ Biol Chem2711996177791778410.1074/jbc.271.30.177798663511 40CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.Cytokine responses in severe" exact="acute" post="respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to"/>
 <result pre="via specific receptorsJ Biol Chem2711996177791778410.1074/jbc.271.30.177798663511 40CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.Cytokine responses in severe acute" exact="respiratory" post="syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesisJ"/>
 <result pre="specific receptorsJ Biol Chem2711996177791778410.1074/jbc.271.30.177798663511 40CheungC.Y.PoonL.L.NgI.H.LukW.SiaS.F.WuM.H.Cytokine responses in severe acute respiratory" exact="syndrome" post="coronavirus-infected macrophages in vitro: possible relevance to pathogenesisJ Virol7920057819782610.1128/JVI.79.12.7819-7826.200515919935"/>
 <result pre="of the chemokine (C-C motif) ligand 2 via a severe" exact="acute" post="respiratory syndrome coronavirus spike–ACE2 signaling pathwayJ Virol8420107703771210.1128/JVI.02560-0920484496 42HeurichA.Hofmann-WinklerH.GiererS.LiepoldT.JahnO.PohlmannS.TMPRSS2 and"/>
 <result pre="the chemokine (C-C motif) ligand 2 via a severe acute" exact="respiratory" post="syndrome coronavirus spike–ACE2 signaling pathwayJ Virol8420107703771210.1128/JVI.02560-0920484496 42HeurichA.Hofmann-WinklerH.GiererS.LiepoldT.JahnO.PohlmannS.TMPRSS2 and ADAM17"/>
 <result pre="chemokine (C-C motif) ligand 2 via a severe acute respiratory" exact="syndrome" post="coronavirus spike–ACE2 signaling pathwayJ Virol8420107703771210.1128/JVI.02560-0920484496 42HeurichA.Hofmann-WinklerH.GiererS.LiepoldT.JahnO.PohlmannS.TMPRSS2 and ADAM17 cleave"/>
 <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ Virol8820141293130710.1128/jvi.02202-1324227843 43ChanJ.F.KokK.H.ZhuZ.ChuH.ToK.K.YuanS.Genomic characterization of"/>
 <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ Virol8820141293130710.1128/jvi.02202-1324227843 43ChanJ.F.KokK.H.ZhuZ.ChuH.ToK.K.YuanS.Genomic characterization of the"/>
 <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ Virol8820141293130710.1128/jvi.02202-1324227843 43ChanJ.F.KokK.H.ZhuZ.ChuH.ToK.K.YuanS.Genomic characterization of the 2019"/>
 <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical" post="pneumonia after visiting WuhanEmerg Microbes Infect9202022123610.1080/22221751.2020.171990231987001 44RiouJ.AlthausC.L.Pattern of early"/>
 <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect9202022123610.1080/22221751.2020.171990231987001 44RiouJ.AlthausC.L.Pattern of early human-to-human"/>
 <result pre="MERS-CoVNat Commun11202022210.1038/s41467-019-13940-631924756 55MulanguS.DoddL.E.DaveyR.T.JrTshiani MbayaO.ProschanM.MukadiD.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsN Engl J Med38120192293230310.1056/NEJMoa191099331774950 56LetkoM.MunsterV.Functional assessment of cell entry"/>
 <result pre="and identification of fusion inhibitorsLancet363200493894710.1016/s0140-6736(04)15788-715043961 59LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.Structure-based discovery of Middle East" exact="respiratory" post="syndrome coronavirus fusion inhibitorNat Commun52014306710.1038/ncomms406724473083 60XiaS.ZhuY.LiuM.LanQ.XuW.WuY.Fusion mechanism of 2019-nCoV"/>
 <result pre="identification of fusion inhibitorsLancet363200493894710.1016/s0140-6736(04)15788-715043961 59LuL.LiuQ.ZhuY.ChanK.H.QinL.LiY.Structure-based discovery of Middle East respiratory" exact="syndrome" post="coronavirus fusion inhibitorNat Commun52014306710.1038/ncomms406724473083 60XiaS.ZhuY.LiuM.LanQ.XuW.WuY.Fusion mechanism of 2019-nCoV and"/>
 <result pre="of MERS-CoV infectionProc Natl Acad Sci U S A11720206771677610.1073/pnas.192208311732054787 65AgostiniM.L.AndresE.L.SimsA.C.GrahamR.L.SheahanT.P.LuX.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 66WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and chloroquine"/>
 <result pre="72MorraM.E.Van ThanhL.KamelM.G.GhazyA.A.AltibiA.M.A.DatL.M.Clinical outcomes of current medical approaches for Middle East" exact="respiratory" post="syndrome: a systematic review and meta-analysisRev Med Virol282018e197710.1002/rmv.197729664167 73StockmanL.J.BellamyR.GarnerP.SARS:"/>
 <result pre="e00420-17 76ChanJ.F.YaoY.YeungM.L.DengW.BaoL.JiaL.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ Infect"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
 <result pre="the application of lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ Korean Med Sci352020e7910.3346/jkms.2020.35.e7932056407 78Iwata-YoshikawaN.OkamuraT.ShimizuY.HasegawaH.TakedaM.NagataN.TMPRSS2 contributes"/>
 <result pre="murine models after coronavirus infectionJ Virol93201910.1128/jvi.01815-18pii: e01815-18 79GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of" exact="coronavirus disease" post="2019 in ChinaN Engl Med2020 Feb 2810.1056/NEJMoa2002032[Epub ahead of"/>
 <result pre="models after coronavirus infectionJ Virol93201910.1128/jvi.01815-18pii: e01815-18 79GuanW.J.NiZ.Y.HuY.LiangW.H.OuC.Q.HeJ.X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl Med2020 Feb 2810.1056/NEJMoa2002032[Epub ahead of"/>
 <result pre="and interferon therapy for critically ill patients with Middle East" exact="respiratory" post="syndrome: a multicenter observational studyClin Infect Dis2019 Jun 2510.1093/cid/ciz544[Epub"/>
 <result pre="ahead of print] 83VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol J220056910.1186/1743-422x-2-6916115318 84SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights into the antiviral"/>
 <result pre="of print] 83VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422x-2-6916115318 84SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights into the antiviral"/>
 <result pre="(Baltimore)982019e1463610.1097/md.000000000001463630921179 87ArabiY.M.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.A.Corticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndromeAm J Respir Crit Care Med197201875776710.1164/rccm.201706-1172OC29161116 88SunM.L.YangJ.M.SunY.P.SuG.H.Inhibitors of RAS"/>
 <result pre="might be a good choice for the therapy of COVID-19" exact="pneumonia" post="[in Chinese]Zhonghua Jie He He Hu Xi Za Zhi"/>
 <result pre="Jie He He Hu Xi Za Zhi [Chinese Journal of" exact="Tuberculosis" post="and Respiratory Diseases]432020E01410.3760/cma.j.issn.1001-0939.2020.0014 89collab: Editorial Board of Chinese Critical"/>
 <result pre="He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and" exact="Respiratory" post="Diseases]432020E01410.3760/cma.j.issn.1001-0939.2020.0014 89collab: Editorial Board of Chinese Critical Care MedicineXuebijing"/>
 <result pre="coronavirus (2019-nCoV) medRxiv2020 Feb 3. doi:10.1101/2020.01.28.20019224. 92LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.The incubation period of" exact="coronavirus disease" post="2019 (COVID-19) from publicly reported confirmed cases: estimation and"/>
 <result pre="(2019-nCoV) medRxiv2020 Feb 3. doi:10.1101/2020.01.28.20019224. 92LauerS.A.GrantzK.H.BiQ.JonesF.K.ZhengQ.MeredithH.The incubation period of coronavirus" exact="disease" post="2019 (COVID-19) from publicly reported confirmed cases: estimation and"/>
 <result pre="[no. 2016JJ3180] and the Valuable Instrument and Equipment Fund of" exact="Central" post="South University [nos. CSUZC2020043 and CSUZC2019046]. Competing interests: None"/>
</results>
